The Quantellect read.As of Nov 19, 2026, 9 active firms cover Quest Diagnostics Incorporated: 3 rate it Buy or better, 6 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $210.00 to $260.00, so the covering firms are broadly aligned. The average target of $241.67 sits 7% below the current $259.52. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.70 next quarter toward $11.98 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Neutral
Strong Buy00%
Buy333%
Neutral667%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$241.67
-6.9% downside
Average target across 9 active firms as of Nov 19, 2026 vs $259.52 current
Highest Target$260.00
Average Target$241.67
Lowest Target$210.00
Detailed analyst forecasts for DGX
Showing 1–10 of 10 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 3 of 9 active firms rate DGX a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DGX EPS & revenue forecast
EPS · NEXT QUARTER
$2.70
Range $2.59 – $2.84 · 10 analysts · +8% YoY
Next period, 10 analysts expect Quest Diagnostics Incorporated to earn $2.70 a share (range $2.59 – $2.84), versus $2.50 a year earlier. Full-year consensus is $11.32, growing to $11.98 the year after.
REVENUE · NEXT QUARTER
$3.0B
Range $3.0B – $3.1B · 10 analysts · +5% YoY
Revenue is expected to reach $3.0B (range $3.0B – $3.1B), +4.6% year-over-year. Full-year consensus is $12.1B, rising to $12.6B next year.
Top analysts covering Quest Diagnostics Incorporated
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DGX.
#1
Erin Wright
Morgan Stanley · Rank #81
Buy
$260.00+0.2% to target
Overall win rate
55%
+ Follow
#2
DM
David Macdonald
Truist Securities · Rank #111
Neutral
$260.00+0.2% to target
Overall win rate
50%
+ Follow
#3
EC
Eric Coldwell
Baird · Rank #127
Neutral
$255.00-1.7% to target
Overall win rate
37%
+ Follow
#4
Kevin Caliendo
UBS · Rank #165
Neutral
$250.00-3.7% to target
Overall win rate
42%
+ Follow
#5
Luke Sergott
Barclays · Rank #267
Buy
$260.00+0.2% to target
Overall win rate
43%
+ Follow
DGX stock forecast FAQ
What is DGX's average 12-month price target?+
The 9 active firms with a live target average $241.67 for Quest Diagnostics Incorporated over the next 12 months, ranging from a $260.00 high to a $210.00 low, as of Nov 19, 2026.
Is DGX stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 9 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 6 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DGX?+
The Street-high target is $260.00 (Barclays), and the Street-low is $210.00 (Evercore ISI Group). The average of all 9 active-firm targets is $241.67.
How many active Wall Street firms cover DGX?+
9 active firms have a recognized rating on Quest Diagnostics Incorporated as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DGX?+
Among analysts who currently cover DGX, Erin Wright of Morgan Stanley has the strongest overall Quantellect track record (Rank #81). Their current call is Buy with a $260.00 target.
What is Quest Diagnostics Incorporated's projected EPS for next quarter?+
The consensus estimate is $2.70 per share (range $2.59 – $2.84) across 10 analysts. Full-year EPS is projected at $11.32, rising to $11.98 the following year.
How much revenue is Quest Diagnostics Incorporated expected to report next quarter?+
Consensus revenue is $3.0B (range $3.0B – $3.1B). Full-year revenue is projected at $12.1B, growing to $12.6B next year.
Have analysts been upgrading or downgrading DGX lately?+
As of Nov 19, 2026, 3 of 9 active firms rate DGX a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DGX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.